4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders

Details for Australian Patent Application No. 2007238690 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Knegtel, Ronald; Charrier, JeanDamien; Kay, David

Agent Spruson & Ferguson

Pub. Number AU-A-2007238690

PCT Pub. Number WO2007/120752

Priority 60/838,720 18.08.06 US; 60/791,327 12.04.06 US

Filing date 12 April 2007

Wipo publication date 25 October 2007

International Classifications

C07D 491/12 (1970.01) Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

13 November 2008 PCT application entered the National Phase

  PCT publication WO2007/120752 Priority application(s): WO2007/120752

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007238693-Ocular imaging

2007238685-Transdermal methods and systems for the delivery of anti-migraine compounds